07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

Voraxaze glucarpidase regulatory update

The Centers for Medicare & Medicaid Services (CMS) will provide hospitals with additional reimbursement payments beyond the predetermined standard rates for the use of BTG's Voraxaze glucarpidase to treat patients with toxic levels of ...
07:00 , Aug 20, 2012 |  BioCentury  |  Regulation

(Part) A for effort

BTG plc and Optimer Pharmaceuticals Inc. are the first drug developers in a decade to take advantage of a program whereby the U.S. Centers for Medicare & Medicaid Services provides hospitals additional reimbursement to treat...
07:00 , Aug 11, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) Carboxypeptidase B2 (CPB2; TAFI); complement 5a (C5a) Mouse and human studies suggest...
08:00 , Feb 24, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers N-terminal truncated carboxypeptidase E (CPE) as a metastasis biomarker In vitro mouse and patient...
07:00 , Oct 1, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Carboxypeptidase E...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Company News

Eden Biodesign, Cancer Research UK deal

CB1954, which is off patent, is in Phase I testing with NAD(P)H dehydrogenase (quinine 2, NQO2) to treat hepatic cell carcinoma (HCC). Cancer Research is conducting that trial for Protherics plc (LSE:PTI; PTIL,...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Clinical News

AZD9684: Development discontinued

AZN said it discontinued development of AZD9684 due to lack of efficacy in Phase II testing. AstraZeneca plc (LSE:AZN; AZN), London, U.K.   Product: AZD9684   Business: Cardiovascular   Molecular target: NA   Description: Carboxypeptidase U (CPU) inhibitor...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Company News

MediciNova, Meiji Seika Kaisha deal

Meiji granted MediciNova a worldwide license to develop and commercialize MN-447 and MN-462. The antithrombotic compounds are in preclinical development for cardiovascular disease. The license excludes Japan and certain Asian countries. MN-447 is a cardioprotective...
00:52 , Nov 2, 2006 |  BC Extra  |  Company News

Meiji licenses compounds to MediciNova, Cerexa

Meiji Seika Kaisha (Tokyo, Japan) was active on Wednesday, striking separate deals in which it granted MediciNova (Osaka:4875) and Cerexa (Alameda, Calif.) licenses for preclinical cardiovascular and infectious disease compounds, respectively. MediciNova received a worldwide...
07:00 , Jul 26, 2004 |  BioCentury  |  Strategy

Redeploying to repurpose

With declining revenues from its information and contract study services, Gene Logic Inc. last week announced an expanded service model based on technology acquired from Millennium Pharmaceuticals Inc. GLGC says the acquisition completes its goal...